Sequenom, GSK Pair Up to Create SNP Assay Portfolio | GenomeWeb

NEW YORK, Aug 29 – Sequenom said Wednesday it had entered an agreement with GlaxoSmithKline to create a SNP assay portfolio that would cover the entire human genome.

"Our immediate goal is to establish a SNP assay portfolio covering all SNPs,” Allen Roses, senior vice president of genetics research at GlaxoSmithKline, said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.